

A Review on Glioblastoma multiforme

Indrani P*

Sri Indu College of Pharmacy, Hyderabad, India

Review Article

Received: 28/11/2016
Revised: 02/12/2016
Accepted: 07/12/2016

*For Correspondence

P. Indrani, Sri indu college of
pharmacy, Hyderabad,
Telangana, India.

E-mail: peddi.indrani@gmail.com

Keywords: Glioblastomas,
Surgery, carcinogenicity, Epstein-
Barr virus

ABSTRACT

A Glioblastoma multiforme happens once abnormal cells type at intervals the brain. There are a unit 2 main sorts of tumors: malignant or cancerous tumors and benign tumors. All types of brain tumors could turn out symptoms that adjust looking on the part of the brain concerned. These could embody headaches, seizures, downside with vision, vomiting, and mental changes. Cancerous tumors are divided into primary tumors that started at intervals the brain and people that unfold from in other places called brain metastasis tumors. The headache is classically worst within the morning and goes away with forcing out. More specific issues could embody issue in walking, speaking and with sensation. As the illness progresses cognitive state could occur.

INTRODUCTION

Glioblastoma multiforme typically have poor outcomes whereas meningiomas typically have smart outcomes. Average 5 year survival rates within the, us square measure thirty third. Metastatic brain tumors square measure additional common than primary brain tumors, with regarding 1/2 metastasis coming back from carcinoma. Primary brain tumors occur in around 250,000 folks a year globally, creating up but two of cancers [1-10]. In youngsters but fifteen, brain tumors square measure second solely to acute lymphocytic leukemia as a reason behind cancer. In Australia the common economic prices of a case of brain cancer is \$1.9 million, the best of any variety of cancer. The reason behind most cases is unknown. The most common styles of primary tumors in adults are: meningiomas and astrocytomas like glioblastomas. In youngsters the foremost common sort is medulloblastomas. Diagnosis is typically by medical exam alongside CAT or resonance imaging. This is then usually confirmed by diagnostic test. Based on the finding the tumors square measure divided into completely different grades or severity. Treatment could embrace some combination of surgery, radiation and therapy. Anticonvulsant medication is required in those that have a seizure. Dexamethasone and water pill could also be accustomed decrease swelling round the tumour [11-20]. Some tumors grow sufficiently slowly that each one that's needed is keeping a watch on that. Treatments that use somebody's system square measure being studied. An outcome depends on the kind of tumour.

Risk factors that will often be concerned include: variety of genetic syndrome like autosomal dominant disease similarly as exposure to the chemical vinyl chloride, Epstein-Barr virus, and radiation. While concern has been raised regarding transportable use the proof isn't clear [21-41].

SIGNS AND SYMPTOMS

The symptom onset – within the timeline of the event of the tumour – depends in several cases, on the character of the tumour however in several cases is additionally associated with the modification of the tumour from "benign" (i.e., slow-growing/late symptom onset) to additional malignant (fast growing/early symptom onset). Visibility of signs and symptoms of brain tumours primarily depends on 2 factors: the tumour size (volume) and tumor location. The instant of symptom onset, once symptoms become apparent either to the person or individuals around them, is a very important milestone within the course of the diagnosing and treatment of the tumour [42-52].

CAUSES

Aside from exposure to vinyl chloride or radiation, there are not any better-known environmental factors related to brain tumors. Mutations and deletions of alleged growth suppressor genes are unit thought to be the explanation for some styles of brain tumors. Individuals with numerous genetic diseases, like Von Hippel-Lindau syndrome, multiple endocrine pathologic processes, von Recklinghausen's disease kind a pair of area unit at high risk of developing brain tumors. Though studies haven't shown any link between telephone radiation and brain tumors, the World Health Organization has classified itinerant radiation on the IARC scale into cluster 2B – probably cancer. Which means that there "could be some risk" of carcinogenicity, therefore further analysis into the semipermanent, serious use of mobile phones must be conducted [53-63].

TREATMENT

Neurosurgeons take the time to watch the evolution of the growth before proposing a management commit to the patient and his/her relatives [64-74]. When a brain tumor is diagnosed, a medical team is fashioned to assess the treatment choices bestowed by the leading Doctor to the patient and his/her family. Given the placement of primary solid neoplasms of the brain in most cases a "do-nothing" possibility is sometimes not bestowed. These varied varieties of treatment are accessible looking on growth sort and site and should be combined to provide the most effective possibilities of survival:

Radiotherapy

The foremost normally used treatment for brain tumors; the tumor is irradiated with beta, x-rays or gamma rays [75-85].

Surgery

Complete or partial surgery of the tumour with the target of removing as several tumour cells as attainable.

Chemotherapy

Chemotherapy may be a treatment possibility for cancer, but it's rarely accustomed treat brain tumors because the blood and brain barrier prevents the medicine from reaching the cancerous cells. Therapy is thought of as a poison that forestalls the expansion and division of all cells within the body as well as cancerous cells [86-96].

A variety of experimental therapies are accessible through clinical trials survival rates in primary brain tumours rely upon the sort of tumor, age, purposeful standing of the patient, the extent of surgical tumour removal and different factors specific to every case [97-99].

CONCLUSION

From the above review it can be concluded that a Glioblastoma multiforme happens once abnormal cells type at intervals the brain. There are 2 main types of tumors: malignant or Glioblastoma multiforme and benign tumors. Glioblastoma multiforme is divided into primary tumors that started at intervals the brain and people that unfold from in other places called brain metastasis tumors. All types of Glioblastoma multiforme could turn out symptoms that adjust looking on the part of the brain concerned. These could embody headaches, seizures, downside with vision, vomiting, and mental changes. The headache is classically worst within the morning and goes away with forcing out. More specific issues could embody issue in walking, speaking and with sensation. As the illness progresses cognitive state could occur.

References

1. Ragnarsson KT, Thomas DC. Principles of Cancer Rehabilitation Medicine. 6th Edn. Holland-Frei Cancer Medicine, 2003.
2. Khan RB, et al. LM of diffusion weighted magnetic resonance imaging in predicting early postoperative outcome of new neurological deficits after brain tumor resection. Neurosurgery. 2006;59:60-66.
3. Kondziolka D, et al. Long-term results after radiosurgery for benign intracranial tumors. Neurosurgery. 2003;53:815-821.

4. Kowalczyk A, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. *Neurosurgery*. 1997;41:1028-1036.
5. Little KM, et al. Surgical management of petroclivale meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. *Neurosurgery*. 2005;56:546-559.
6. Qureshi AI, et al. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. *Crit Care Med*. 2000;28:1556-1564.
7. Stafford SL, et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. *Neurosurgery*. 2001;49:1029-1037.
8. Huang ME, et al. Functional outcomes and quality of life in patients with brain tumors: a preliminary report. *Arch Phys Med Rehabil*. 2001;82:1540-1546.
9. Huang ME, et al. Functional outcomes and quality of life in patients with brain tumours: a review of the literature. *Brain Inj*. 2001;15:843-856.
10. O'Dell MW, et al. Functional outcome of inpatient rehabilitation in persons with brain tumors. *Arch Phys Med Rehabil*. 1998;79:1530-1534.
11. Chi MS, et al. Sirolimus and Hydroxychloroquine as an Add-On to Standard Therapy for Glioblastoma Multiforme: Case Report. *J Biomol Res Ther*. 2016;5:141.
12. Gattass CR. Exploring Melissa Officinalis Properties for Glioblastoma Multiforme Treatment. *Chemo Open Access*. 2015;4:162.
13. Schijns VEJC, et al. A Personalized Immunotherapeutic Vaccine (Gliovac Or ERC1671) Against Recurrent Glioblastoma Multiforme (GBM). *Brain Disord Ther*. 2015;S2:006.
14. Rasime K. Epigenetics of Glioblastoma Multiforme. *J Clinic Res Bioeth*. 2015;6:225.
15. Banerjee HN, et al. Deciphering the Finger Prints of Brain Cancer Glioblastoma Multiforme from Four Different Patients by Using Near Infrared Raman Spectroscopy. *J Cancer Sci Ther*. 2015;7:44-47
16. Mullins CS, et al. A Comprehensive Approach to Patient-individual Glioblastoma Multiforme Model Establishment. *J Cancer Sci Ther*. 2014;6:177-187.
17. Dewan S, et al. Irinotecan and BCNU Impregnated Wafers Used in Combination, for the Treatment of Patients with Recurrent Glioblastoma Multiforme. *J Carcinogene Mutagene*. 2010;1:101.
18. Slovackova B, et al. Neurocognitive Functioning in Glioblastoma Multiforme Patients during Radiotherapy Plus Concomitant and Adjuvant Temozolomide: A Case Series. *J Integr Oncol* 2014;3:118.
19. Mathur T, et al. Mathur S. A Case of Glioblastoma Multiforme Masquerading as Rapidly Progressive Dementia. *Brain Disord Ther*. 2014;3:113.
20. Tandle AT, et al. Urinary Metabolomic Profiling of Patients with Glioblastoma Multiforme. *J Proteomics Bioinform*. 2013;S6:003.
21. Banerjee HN, et al. C-6 Ceramide Induces p53 Dependent Apoptosis in Human Astrocytoma Grade4 (Glioblastoma Multiforme) Cells. *J Cancer Sci Ther*. 2012;4:012-015.
22. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol*. 2007;114:97-109.
23. Darefsky AS, et al. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. *Cancer*. 2012;118:2163-2172.
24. Keime-Guibert F, et al. Radiotherapy for glioblastoma in the elderly. *N Engl J Med*. 2007;356:1527-1535.
25. Mirimanoff RO, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. *J Clin Oncol*. 2006;24:2563-2569.
26. Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370:699-708.
27. Chinot OL, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370:709-722.

28. Sui X, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. *Cell Death Dis.* 2013;4:e838.
29. Lefranc F and Kiss R. Autophagy, the Trojan horse to combat glioblastomas. *Neurosurg Focus* 2006;20:E7.
30. Sotelo J, et al. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2006;144:337-343.
31. Duffy A, et al. Autophagy modulation: a target for cancer treatment development. *Cancer Chemother Pharmacol.* 2015;75:439-447.
32. Bonuccelli G, et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle.* 2010;9:3506-3514.
33. Martinez-Outschoorn UE, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. *Cell Cycle.* 2010;9:3256-3276.
34. Martinez-Outschoorn UE, et al. The autophagic tumor stroma model of cancer or "battery-operated tumor growth": a simple solution to the autophagy paradox. *Cell Cycle.* 2010;9:4297-4306.
35. Chi KH, et al. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. *Oncotarget.* 2015;6:16735-16745.
36. Combs SE, et al. Stress response leading to resistance in glioblastoma-the need for innovative radiotherapy (irt) concepts. *Cancers (Basel).* 2016;8:15.
37. Kaza N, et al. Autophagy in brain tumors: a new target for therapeutic intervention. *Brain Pathol.* 2011;22:89-98.
38. Kanzawa T, et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. *Cell Death Differ.* 2004;11:448-457.
39. Arcella A, et al. Rapamycin inhibits the growth of glioblastoma. *Brain Res.* 2012;1495:37-51.
40. Bouchard F, et al. EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth. *Blood.* 2012;116:759-766.
41. Eisenberg-Lerner A and Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. *Apoptosis.* 2009;14:376-391.
42. Queiroz RM, et al. Apoptosis-Inducing Effects of Melissa officinalis L. Essential Oil in Glioblastoma Multiforme Cells. *Cancer Inv.* 2014;32:226-235.
43. Longley DB and Johnston PG. Molecular mechanisms of drug resistance. *J Pathol.* 2005;205: 275-292.
44. Fletcher JI, et al. ABC transporters in cancer: more than just drug efflux pumps. *Nature Rev cancer.* 2010;10:147-156.
45. Indran IR, et al. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. *Biochim Biophys Acta.* 2011;1807:735-745.
46. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005;352:987-996.
47. Nakagawa T, et al. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. *Neuropathol* 2009;29:379-388.
48. Benyahia B, et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. *J Neurooncol.* 2004;65:65-70.
49. Garrido W, et al. FK506 confers chemosensitivity to anticancer drugs in glioblastomamultiforme cells by decreasing the expression of the multiple resistance-associated protein-1. *Biochem Biophys Res Commun.* 2011;411:62-68.
50. Zhang WB, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. *J Biol Chem.* 2010;285:40461-40471.

51. Oliva R, et al. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. *PLoS One*. 2011;6:1-10.
52. Happold C, et al. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. *J Neurochem*. 2012;122:444-455.
53. Bayala B, et al. Chemical Composition, Antioxidant, Anti-Inflammatory and Anti-Proliferative Activities of Essential Oils of Plants from Burkina Faso *Plos One*. 2013;9:e92122.
54. Russo R, et al. Exploitation of Cytotoxicity of Some Essential Oils for Translation in Cancer Therapy. *Evid Based Complement Alternat Med*. 2015;397821:9.
55. de Sousa AC, et al. Melissa officinalis L. essential oil: antitumoral and antioxidant activities *J Pharm Pharmacol*. 2004;56:677-681.
56. Dudai N, et al. Citral is a new inducer of caspase-3 in tumor cell lines. *Planta Med*. 2005;71:484-488.
57. Chaouki W, et al. Citral inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF-7 cells. *Fundam Clin Pharmacol*. 2009;23:549-556.
58. Barker FG, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. *Neurosurgery*. 1998;42:709-720.
59. Bota DA, et al. Use of ERC-1671 Vaccine in a patient with recurrent glioblastoma multiforme after progression during Bevacizumab Therapy : first published report. *Perm J*. 2015;19:41-46.
60. SchijnsVEJC, et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. *Vaccine*. 2015;33:2690-2696.
61. Chang DZ, et al. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. *Hematology*. 2004;9:207-215.
62. Newton HB. Primary brain tumors: review of etiology, diagnosis and treatment. *Am Fam Physician*. 1994;49:787-797.
63. Kleihues P, et al. The WHO classification of tumors of the nervous system. *J Neuropathol Exp Neurol*. 2002;61: 215-225.
64. Davis FG and McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. *Expert Rev Anticancer Ther*. 2001;1:395-401.
65. Wrensch M, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. *Neuro Oncol*. 2002;4:278-299.
66. Fine HA, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. *Cancer*. 1993;71:2585-2597.
67. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. *Lancet*. 2002;359:1011-1018.
68. Newton HB, et al. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. *Ann Pharmacother*. 1999;33:816-832.
69. Newton HB. Clinical pharmacology of brain tumour chemotherapy In: Newton HB (ed.) *Handbook of brain tumor chemotherapy*. Elsevier. 2006;21-43.
70. Mischel PS and Cloughesy TF. Targeted molecular therapy of GBM. *Brain Pathol*. 2003;13:52-61.
71. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. *Expert Rev Anticancer Ther*. 2003;3:595-614.
72. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. *Expert Rev Anticancer Ther*. 2004;4:105-128.
73. Newton HB. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle. *Expert Rev Anticancer Ther*. 2005;5:355-378.
74. Rich JN and Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. *Nat Rev Drug Discov* 2004;3:430-446.

75. Tremont-Lukats IW and Gilbert MR. Advances in molecular therapies in patients with brain tumors. *Cancer Control*. 2003;10:125-137.
76. Thon N, Kreth S, Kreth FW. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. *Onco Targets Ther*. 2013;6:1363-1372.
77. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*. 2008;455:1061-1068.
78. Amatya VJ, et al. TP53 promoter methylation in human gliomas. *Acta Neuropathol*. 2005;110:178-184.
79. Brower JV, et al. MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. *Neurochem Int*. 2014;77:68-77.
80. Saito Y, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell*. 2006;9:435-443.
81. Lujambio A, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res*. 2007;67:1424-1429.
82. Banerjee H, et al. Search for a novel biomarker for the brain cancer astrocytoma by using surface enhanced laser desorption/ionisation (SELDI) technique. *Cell MolBiol*. 2004;50:733-736.
83. Banerjee HN and Zhang L. Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy. *Mol Cell Biochem* 2007;295:237-240.
84. Diehl B, et al. The Benefits of a High-Performance, Handheld Raman Spectrometer for the Rapid Identification of Pharmaceutical Raw Materials. *Eur Pharm Rev*. 2012;17:3-8.
85. Kallaway C, et al. Advances in the clinical application of Raman spectroscopy for cancer diagnostics. *Photodiagnosis Photodyn Ther*. 2013;10:207-219.
86. Horsnell JD, et al. Raman spectroscopy--a potential new method for the intra-operative assessment of axillary lymph nodes. *Surgeon*. 2012;10:123-127.
87. Mannie MD and Norris MS. MHC class-II-restricted antigen presentation by myelin basic protein-specific CD4+ T cells causes prolonged desensitization and outgrowth of CD4- responders. *Cell Immunol*. 2001;212:51-62.
88. Mannie MD, et al. IL-4 responsive CD4+ T cells specific for myelin basic protein: IL-2 confers a prolonged postactivation refractory phase. *Immunol Cell Biol*. 2003;81:8-19.
89. Norris MS, et al. Interleukin-2 promotes antigenic reactivity of rested T cells but prolongs the postactivation refractory phase of activated T cells. *Cell Immunol*. 2001;211:51-60.
90. Notingher I, et al. Spectroscopic study of human lung epithelial cells (A549) in culture: living cells versus dead cells. *Biopolymers* 2003;72:230-240.
91. Otto C, et al. Confocal Raman microspectroscopy of the activation of single neutrophilic granulocytes. *EurBiophys J*. 1998;27:582-589.
92. Patel DM, et al. Intercellular exchange of class II MHC complexes: ultrastructural localization and functional presentation of adsorbed I-A/peptide complexes. *Cell Immunol*. 2001;214:21-34.
93. Peticolas WL, et al. Laser Raman microscopy of chromosomes in living eukaryotic cells: DNA polymorphism in vivo. *J Raman Spectrosc*. 1996;27:571.
94. Puppels GJ, et al. Studying single living cells and chromosomes by confocal Raman microspectroscopy. *Nature*. 1990;347:301-333.
95. Puppels GJ, et al. Raman microspectroscopic approach to the study of human granulocytes. *Biophys J*. 1991;60: 1046-1056.
96. Salmaso BL, et al. Resonance Raman microspectroscopic characterization of eosinophil peroxidase in human eosinophilic granulocytes. *Biophys J*. 1994;67:436-446.
97. Sandstrom PA, et al. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. *J LeukocBiol*. 1994;55:221-216.
98. Sijtsema NM, et al. Resonance Raman microspectroscopy of myeloperoxidase and cytochrome b558 in human neutrophilic granulocytes. *Biophys J*. 1998;74:3250-3255.

99. Sijtsema NM, et al. Intracellular reactions in single human granulocytes upon phorbolmyristate acetate activation using confocal Raman microspectroscopy. *Biophys J.* 2007;8:2606-2613.